The Obama administration announced Monday afternoon that the National Institutes of Health will redirect $100 million in funding to establish a new program to find better treatments--and eventually, a cure--for HIV and AIDS.
If timing is everything, then Alere stands to gain plenty, thanks to the Affordable Care Act. The new law mandates reimbursement for HIV testing from both public and private insurers, and Alere recently rolled out a new, first-of-its-kind combo HIV diagnostic in the U.S.
Scientists have unraveled one of the mysteries of HIV--they've mapped out the structure of an envelope protein within the virus, long known as an extremely difficult target.
A cure for HIV/AIDS may not be as close as scientists believed, according to a new study by Johns Hopkins researchers. In a report published Oct. 24 in the journal Cell, investigators found a new obstacle that could hinder current efforts to find a cure for the immune-compromising disease.
When NIH canned its HIV vaccine trial in April, the field, yet again, lost its brightest hope. Since then, NIH has continued to monitor participants in the trial, and this week it presented an update in the New England Journal of Medicine.
The ring, which delivers a powdered version of the antiretroviral drug tenofovir for up to 30 days at a time, showed a 100% success rate in animal models and will enter a clinical trial in November.
Researchers at Northwestern University have developed an intravaginal ring that releases an antiretroviral drug over a long period of time, a replacement for such regimens as daily pills or vaginal gels that have low levels of compliance.
HIV diagnostics and other tests in the developed and developing worlds could become far quicker and cheaper with a device developed by a Cambridge, MA, company.
An antifungal drug ousted HIV from cells with the virus, according to a new study, pointing to a potential new way to treat the infection, which affects an estimated 1.2 million people in the U.S.
Profectus BioSciences, a vaccine developer with a focus on DNA-based applications, began a Phase I clinical trial of its HIV vaccine, which makes use of the TriGrid electroporation delivery system the company licensed from Ichor Medical Systems.